

**Amendments to the Claims:**

This listing of the claims will replace all prior versions, and listings, of the claims in the application:

**Listing of the Claims:**

Claims 1-16 (canceled).

Claim 17 (currently amended): A method of blocking binding of a chemokine capable of binding an M3 protein of MHV68 to a receptor for the chemokine on the surface of a cell, comprising

contacting the cell with a M3 protein of MHV68 ~~or functional homologue thereof~~ which binds to the chemokine, thereby blocking the binding of the chemokine to the receptor, wherein the chemokine, the receptor, the M3 protein of MHV68, or a combination thereof are labeled or unlabeled.

Claim 18 (previously presented): The method of claim 17, wherein the chemokine is a CXC, CC, C, or a CX3C chemokine.

Claim 19 (previously presented): The method of claim 18, wherein the chemokine is a human or a mouse chemokine.

Claim 20 (previously presented): The method of claim 17, wherein the chemokine is lymphotactin, RANTES, MIP-1 alpha, MCP-1, MCP-4, IL-8, murine KC, murine MIP2, human GCP2, human IP10, fractalkine, murine LIX, MIP-1, or secondary lymphoid tissue chemokine SLC.

Claim 21 (canceled).

Claim 22 (previously presented): The method of claim 17, wherein the cell is *in vitro*.

Claim 23 (previously presented): The method of claim 17, wherein the cell is *in vivo*.

Claim 24 (previously presented): The method of claim 17, wherein the M3 protein of MHV68 is labeled.

Claim 25 (previously presented): The method of claim 17, wherein the chemokine is labeled.

Claim 26 (previously presented): The method of claim 17, wherein the receptor for the chemokine is labeled.

Claim 27 (previously presented): The method of claim 17, wherein the cell is a skin cell.

Claim 28 (currently amended): ~~The method of claim 17,~~ A method of blocking binding of a chemokine capable of binding an M3 protein of MHV68 to a receptor for the chemokine on the surface of a cell, comprising

contacting the cell with a M3 protein of MHV68 which binds to the chemokine, thereby blocking the binding of the chemokine to the receptor,

wherein the chemokine, the receptor, the M3 protein of MHV68, or a combination thereof, are labeled or unlabeled

wherein the M3 protein of MHV68, ~~or homologue~~ is a coupled protein.

Claim 29 (previously presented): The method of claim 17, wherein the chemokine comprises lymphotactin.

Claim 30 (previously presented): The method of claim 17, wherein the chemokine comprises RANTES.

Claim 31 (previously presented): The method of claim 17, wherein the chemokine comprises MIP-1-alpha.

Claim 32 (previously presented): The method of claim 17, wherein the chemokine comprises MCP-1.

Claim 33 (previously presented): The method of claim 17, wherein the chemokine comprises MCP-4.

Claim 34 (previously presented): The method of claim 17, wherein the chemokine comprises IL-8.

Claim 35 (previously presented): The method of claim 17, wherein the chemokine comprises human GCP2.

Claim 36 (previously presented): The method of claim 17, wherein the chemokine comprises human IP10.

Claim 37 (previously presented): The method of claim 17, wherein the chemokine comprises fractalkine.

Claim 38 (previously presented): The method of claim 17, wherein the chemokine comprises secondary lymphoid tissue chemokine SLC.

Claim 39 (previously presented): The method of claim 17, wherein the chemokine is a human chemokine.